{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T08:56:06Z","timestamp":1767084966227,"version":"3.44.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.semarthrit.2023.152206","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T11:42:17Z","timestamp":1682509337000},"page":"152206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Therapeutic approach to central nervous system involvement of Beh\u00e7et's disease"],"prefix":"10.1016","volume":"61","author":[{"given":"Jurgen","family":"Sota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulen","family":"Hatemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2023.152206_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","article-title":"Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Beh\u00e7et's disease","volume":"14","author":"Cantarini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0002","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.autrev.2017.12.006","article-title":"Beh\u00e7et's disease: new insights into pathophysiology, clinical features and treatment options","volume":"17","author":"Greco","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0003","first-page":"S2","article-title":"On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus. 1937","volume":"28","author":"Beh\u00e7et","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"Pt 11","key":"10.1016\/j.semarthrit.2023.152206_bib0004","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/brain\/122.11.2171","article-title":"Clinical patterns of neurological involvement in Beh\u00e7et's disease: evaluation of 200 patients. The Neuro-Beh\u00e7et Study Group","volume":"122","author":"Akman-Demir","year":"1999","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0005","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","article-title":"The long-term mortality and morbidity of Beh\u00e7et syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center","volume":"82","author":"Kural-Seyahi","year":"2003","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0006","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s11739-019-02248-4","article-title":"Beh\u00e7et's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics","volume":"15","author":"Sota","year":"2020","journal-title":"Intern Emerg Med"},{"issue":"Pt 11","key":"10.1016\/j.semarthrit.2023.152206_bib0007","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/brain\/122.11.2183","article-title":"Neurological complications in Beh\u00e7et's syndrome","volume":"122","author":"Kidd","year":"1999","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0008","article-title":"Neuro-Behcet's disease: an update on diagnosis, differential diagnoses, and treatment","volume":"39","author":"Borhani-Haghighi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0009","doi-asserted-by":"crossref","DOI":"10.1007\/s11739-022-03038-1","article-title":"Development and implementation of the AIDA International Registry for patients with Beh\u00e7et's disease","author":"Vitale","year":"2022","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0010","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1007\/s00415-013-7209-3","article-title":"Diagnosis and management of Neuro-Beh\u00e7et's disease: international consensus recommendations","volume":"261","author":"Kalra","year":"2014","journal-title":"J Neurol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0011","doi-asserted-by":"crossref","first-page":"10196","DOI":"10.1038\/s41598-017-09938-z","article-title":"Distinct clinical features between acute and chronic progressive parenchymal neuro-Beh\u00e7et disease: meta-analysis","volume":"7","author":"Ishido","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0012","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/art.38351","article-title":"Long-term outcome of neuro-Beh\u00e7et's disease","volume":"66","author":"Noel","year":"2014","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0013","first-page":"1015","article-title":"CNS involvement in neuro-Beh\u00e7et syndrome: an MR study","volume":"20","author":"Ko\u00e7er","year":"1999","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0014","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.2174\/1381612825666191209115431","article-title":"\u03b2-amyloid and oxidative stress: perspectives in drug development","volume":"25","author":"Caruso","year":"2020","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0015","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00415-010-5885-9","article-title":"Cerebral venous thrombosis in Beh\u00e7et's disease: a systematic review","volume":"258","author":"Aguiar de Sousa","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0016","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/NRL.0b013e31805778d1","article-title":"Peripheral nervous system involvement in patients with Beh\u00e7et disease","volume":"13","author":"Atasoy","year":"2007","journal-title":"Neurologist"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0017","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00296-020-04650-0","article-title":"Behcet's disease with peripheral nervous system involvement successfully treated with golimumab: a case report and review of the literature","volume":"41","author":"Yao","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0018","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0019","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Beh\u00e7et's syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s00393-013-1307-6","article-title":"Etanercept therapy in Beh\u00e7et's disease. The tight control strategy in refractory disease","volume":"73","author":"Mohammed","year":"2014","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0021","doi-asserted-by":"crossref","first-page":"e3863","DOI":"10.1097\/MD.0000000000003863","article-title":"Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study","volume":"95","author":"Hibi","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0022","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/mr\/roab008","article-title":"Apremilast in a Japanese subgroup with Beh\u00e7et's syndrome: results from a Phase 3, randomised, double-blind, placebo-controlled study","volume":"32","author":"Takeno","year":"2022","journal-title":"Mod Rheumatol"},{"issue":"132","key":"10.1016\/j.semarthrit.2023.152206_bib0023","doi-asserted-by":"crossref","first-page":"80","DOI":"10.55563\/clinexprheumatol\/ra8ize","article-title":"Apremilast for oral ulcers associated with active Beh\u00e7et's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial","volume":"39","author":"Hatemi","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0024","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","article-title":"Use of Gevokizumab in patients with beh\u00e7et's disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study","volume":"26","author":"Tugal-Tutkun","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0025","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Beh\u00e7et syndrome. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0026","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09273940701299370","article-title":"A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Beh\u00e7et's disease","volume":"15","author":"Buggage","year":"2007","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0027","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-017-1222-3","article-title":"Treatment of mucocutaneous manifestations in Beh\u00e7et's disease with anakinra: a pilot open-label study","volume":"19","author":"Grayson","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0028","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/BOR.0000000000000854","article-title":"A treat-to-target approach is needed for Beh\u00e7et's syndrome","volume":"34","author":"Hatemi","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0029","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2169\/internalmedicine.4705-20","article-title":"Recommendations for the Management of Neuro-Beh\u00e7et's Disease by the Japanese National Research Committee for Beh\u00e7et's Disease","volume":"59","author":"Hirohata","year":"2020","journal-title":"Intern Med Tokyo Jpn"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0030","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-510X(98)00165-8","article-title":"Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease","volume":"159","author":"Hirohata","year":"1998","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0031","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/s10165-011-0533-5","article-title":"Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis","volume":"22","author":"Hirohata","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0032","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/art.1780400425","article-title":"Azathioprine in Behcet's syndrome: effects on long-term prognosis","volume":"40","author":"Hamuryudan","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0033","first-page":"S64","article-title":"Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Beh\u00e7et's disease with parenchymal involvement: presentation of four cases","volume":"29","author":"Shugaiv","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0034","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13256-017-1261-z","article-title":"Frosted branch angiitis and cerebral venous sinus thrombosis as an initial onset of neuro-Beh\u00e7et's disease: a case report and review of the literature","volume":"11","author":"A","year":"2017","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0035","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/1756-185X.12265","article-title":"Neuro-beh\u00e7et's disease in South Korea: clinical characteristics and treatment response","volume":"17","author":"Yoon","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0036","first-page":"600","article-title":"[Neuro-Beh\u00e7et: a follow-up of 4 cases treated with chlorambucil]","volume":"12","author":"Mateos-Colino","year":"1995","journal-title":"An Med Interna Madr Spain 1984"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0037","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0002-9343(84)90753-8","article-title":"Chlorambucil in the treatment of uveitis and meningoencephalitis of Beh\u00e7et's disease","volume":"76","author":"O'Duffy","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0038","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10067-016-3417-4","article-title":"Adalimumab effectiveness in Beh\u00e7et's disease: short and long-term data from a multicenter retrospective observational study","volume":"36","author":"Vitale","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0039","first-page":"S54","article-title":"Efficacy of adalimumab in patients with Beh\u00e7et's disease unsuccessfully treated with infliximab","volume":"29","author":"Olivieri","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","article-title":"Anti-TNF agents for Beh\u00e7et's disease: analysis of published data on 369 patients","volume":"41","author":"Arida","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0041","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","article-title":"Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et's disease: multicenter study of 124 patients","volume":"62","author":"Vallet","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0042","first-page":"S102","article-title":"Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab","volume":"28","author":"Leccese","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0043","doi-asserted-by":"crossref","first-page":"e3550","DOI":"10.1097\/MD.0000000000003550","article-title":"Efficacy of Anti-TNF\u03b1 in Severe and Refractory Neuro-Behcet Disease: an Observational Study","volume":"95","author":"Desbois","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0044","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/rheumatology\/kes130","article-title":"Adalimumab for the treatment of Beh\u00e7et's disease: experience in 19 patients","volume":"51","author":"Perra","year":"2012","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0045","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pediatrneurol.2010.04.021","article-title":"Pediatric neuro-Beh\u00e7et's disease responsive to adalimumab","volume":"43","author":"Robinson","year":"2010","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0046","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13052-016-0291-2","article-title":"Autoimmune sensorineural hearing loss as presenting manifestation of paediatric Beh\u00e7et disease responding to adalimumab: a case report","volume":"42","author":"Marsili","year":"2016","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0047","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1212\/NXI.0000000000000258","article-title":"Infliximab is a plausible alternative for neurologic complications of Beh\u00e7et disease","volume":"3","author":"Zeydan","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0048","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.23345","article-title":"Infliximab for the treatment of Neuro-Beh\u00e7et's disease: a case series and review of the literature","volume":"59","author":"Pipitone","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0049","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-009-1213-z","article-title":"One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh\u00e7et's disease refractory to standard immunosuppressive drugs","volume":"31","author":"Giardina","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0050","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1179\/2045772311Y.0000000050","article-title":"Longitudinally extensive transverse myelitis as the sole presentation of neuro-Beh\u00e7et's disease responding to infliximab","volume":"35","author":"Coulter","year":"2012","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0051","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1179\/2045772314Y.0000000209","article-title":"Recurrent longitudinal extensive transverse myelitis in a neuro-Beh\u00e7et syndrome treated with infliximab","volume":"38","author":"Uyguno\u011flu","year":"2015","journal-title":"J Spinal Cord Med"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0052","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/1756-185X.14209","article-title":"Infliximab therapy in parenchymal neuro-Beh\u00e7et's disease: a single-center experience","volume":"24","author":"Yalcin Kehribar","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0053","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.clineuro.2006.11.002","article-title":"A patient with neuro-Beh\u00e7et's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade","volume":"109","author":"Alty","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0054","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s10067-017-3627-4","article-title":"Long-term efficacy and safety of golimumab in the treatment of multirefractory Beh\u00e7et's disease","volume":"36","author":"Vitale","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0055","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/14397595.2017.1285857","article-title":"Certolizumab Pegol treatment in Behcet's disease with different organ involvement: a multicenter retrospective observational study","volume":"27","author":"Lopalco","year":"2017","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0056","first-page":"1637","article-title":"A case of neuromyotonia in Beh\u00e7et disease during TNF-\u03b1 antagonist therapy","volume":"35","author":"Belluzzo","year":"2014","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0057","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.autrev.2018.09.005","article-title":"The future landscape of biosimilars in rheumatology: where we are where we are going","volume":"18","author":"Scheinberg","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0058","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s11739-018-1970-3","article-title":"Long-term effectiveness and safety of switching from originator to biosimilar infliximab in patients with Beh\u00e7et's disease","volume":"14","author":"Lopalco","year":"2019","journal-title":"Intern Emerg Med"},{"issue":"121","key":"10.1016\/j.semarthrit.2023.152206_bib0059","first-page":"111","article-title":"Biosimilar infliximab for Beh\u00e7et's syndrome: a case series","volume":"37","author":"Dincses","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0060","first-page":"171","article-title":"Interleukin-1 Inhibition in Beh\u00e7et's disease","volume":"18","author":"Vitale","year":"2016","journal-title":"Isr Med Assoc J IMAJ"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0061","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-149-4-200808190-00018","article-title":"Resistant Beh\u00e7et disease responsive to anakinra","volume":"149","author":"Botsios","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0062","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcet's disease: a case series","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0063","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","article-title":"Efficacy and safety profile of anti-interleukin-1 treatment in Beh\u00e7et's disease: a multicenter retrospective study","volume":"35","author":"Emmi","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0064","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000358125","article-title":"Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Beh\u00e7et's disease: a case series","volume":"228","author":"Vitale","year":"2014","journal-title":"Dermatol Basel Switz"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0065","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/1756-185X.12680","article-title":"Interleukin-1 blockade in neuro-Beh\u00e7et's disease: a case-based reflection","volume":"20","author":"Vitale","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0066","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/clin.1996.4268","article-title":"Cerebrospinal fluid interleukin-6 in progressive Neuro-Beh\u00e7et's syndrome","volume":"82","author":"Hirohata","year":"1997","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0067","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cyto.2008.10.007","article-title":"Interleukin-6 in neuro-Beh\u00e7et's disease: association with disease subsets and long-term outcome","volume":"44","author":"Akman-Demir","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0068","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clineuro.2011.10.024","article-title":"Tocilizumab treatment for neuro-Behcet's disease, the first report","volume":"114","author":"Shapiro","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0069","first-page":"S73","article-title":"Refractory neuro-Beh\u00e7et treated by tocilizumab: a case report","volume":"30","author":"Urbaniak","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neurol.2017.02.006","article-title":"Efficacy and safety of tocilizumab in neuro-Beh\u00e7et's disease: a case report","volume":"173","author":"Essaadouni","year":"2017","journal-title":"Rev Neurol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0071","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.semarthrit.2014.08.004","article-title":"Tocilizumab for severe refractory neuro-Beh\u00e7et: three cases IL-6 blockade in neuro-Beh\u00e7et","volume":"44","author":"Addimanda","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"132","key":"10.1016\/j.semarthrit.2023.152206_bib0072","doi-asserted-by":"crossref","first-page":"37","DOI":"10.55563\/clinexprheumatol\/9ipkcs","article-title":"Tocilizumab in Beh\u00e7et's disease with refractory ocular and\/or neurological involvement: response according to different clinical phenotypes","volume":"39","author":"Atienza-Mateo","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0073","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10067-014-2589-z","article-title":"Paradoxical mucocutaneous flare in a case of Beh\u00e7et's disease treated with tocilizumab","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0074","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-204366","article-title":"Treatment of myelitis in Beh\u00e7et's disease with rituximab","volume":"2014","author":"Messina","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0075","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1007\/s00415-015-7897-y","article-title":"Rituximab is effective in severe treatment-resistant neurological Beh\u00e7et's syndrome","volume":"262","author":"Kidd","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0076","article-title":"Case report: repeated low-dose rituximab treatment is effective in relapsing Neuro Beh\u00e7et's disease","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Neurol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0077","first-page":"139","article-title":"Neuro-Beh\u00e7et's disease presenting with tumour-like lesions and responding to rituximab","volume":"32","author":"Jade","year":"2016","journal-title":"J Clin Neurosci Off J Neurosurg Soc Australas"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0078","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577308","article-title":"Rituximab as an effective therapeutic option in refractory Neuro-Beh\u00e7et syndrome","volume":"346","author":"Garcia-Estrada","year":"2020","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0079","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","article-title":"Remission induction in Beh\u00e7et's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H","volume":"42","author":"Lockwood","year":"2003","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0080","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.3899\/jrheum.141344","article-title":"Alemtuzumab as remission induction therapy in Beh\u00e7et disease: a 20-year experience","volume":"42","author":"Mohammad","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0081","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00041327-200106000-00011","article-title":"Interferon-alpha 2a treatment of neuro-Behcet disease","volume":"21","author":"Nichols","year":"2001","journal-title":"J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0082","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/ard.62.5.492","article-title":"Effects of interferon alpha treatment on the clinical course of refractory Beh\u00e7et's disease: an open study","volume":"62","author":"Calg\u00fcneri","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0083","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s10067-004-0944-1","article-title":"Transverse myelitis in a patient with Behcet's disease: favorable outcome with a combination of interferon-alpha","volume":"24","author":"Calg\u00fcneri","year":"2005","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0084","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/rheumatology\/ken172","article-title":"Interferon-alpha\u2013a new therapeutic option in refractory juvenile Beh\u00e7et's disease with CNS involvement","volume":"47","author":"Kuemmerle-Deschner","year":"2008","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0085","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/qjmed\/hcq125","article-title":"Interferon-\u03b1 treatment for acute myelitis and intestinal involvement in severe Beh\u00e7et's disease","volume":"103","author":"Monastirli","year":"2010","journal-title":"QJM Mon J Assoc Physicians"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0086","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.seizure.2008.05.008","article-title":"Epileptic seizures as the sole manifestation of neuro-Beh\u00e7et's disease: complete control under interferon-alpha treatment","volume":"17","author":"Chroni","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0087","first-page":"S175","article-title":"Interferon alfa-associated depression in patients with Beh\u00e7et's syndrome: a prospective controlled study","volume":"32","author":"Keskin","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0088","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.autrev.2012.02.006","article-title":"Intravenous immunoglobulin: exploiting the potential of natural antibodies","volume":"11","author":"Kaveri","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0089","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.autrev.2012.04.006","article-title":"Intravenous immunoglobulin for the treatment of Crohn's disease","volume":"12","author":"Rogosnitzky","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0090","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.autrev.2012.08.017","article-title":"Tregitope update: mechanism of action parallels IVIg","volume":"12","author":"Cousens","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0091","first-page":"238","article-title":"Efficacy and safety of intravenous immunoglobulin treatment in refractory behcet's disease with different organ involvement: a case series","volume":"18","author":"Cantarini","year":"2016","journal-title":"Isr Med Assoc J IMAJ"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0092","first-page":"88","article-title":"Coexistence of Guillain-Barr\u00e9 syndrome and Beh\u00e7et's disease","volume":"31","author":"Shugaiv","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0093","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3109\/14397595.2014.891496","article-title":"Analysis of various factors on the relapse of acute neurological attacks in Beh\u00e7et's disease","volume":"24","author":"Hirohata","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0094","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/rheumatology\/key153","article-title":"Beh\u00e7et's disease as a causative factor of cerebral venous sinus thrombosis: subgroup analysis of data from the VENOST study","volume":"58","author":"Uluduz","year":"2019","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0095","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00415-010-5885-9","article-title":"Cerebral venous thrombosis in Beh\u00e7et's disease: a systematic review","volume":"258","author":"Aguiar de Sousa","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0096","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1136\/jnnp.64.3.382","article-title":"Beh\u00e7et's syndrome: a report of 41 patients with emphasis on neurological manifestations","volume":"64","author":"Farah","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0097","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3389\/fimmu.2019.01085","article-title":"Beh\u00e7et's syndrome as a model of thrombo-inflammation: the role of neutrophils","volume":"10","author":"Emmi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0098","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neurol.2017.06.021","article-title":"Can anticoagulation therapy in cerebral venous thrombosis associated with Beh\u00e7et's disease be stopped without relapse?","volume":"174","author":"Roriz","year":"2018","journal-title":"Rev Neurol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0099","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1474-4422(09)70015-8","article-title":"Neuro-Beh\u00e7et's disease: epidemiology, clinical characteristics, and management","volume":"8","author":"Al-Araji","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0100","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1526-4610.2007.01041.x","article-title":"The prevalence and characteristics of different types of headache in patients with Beh\u00e7et's disease, a case-control study","volume":"48","author":"Borhani Haghighi","year":"2008","journal-title":"Headache"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0101","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1468-2982.2005.01017.x","article-title":"Headache in Beh\u00e7et's disease","volume":"26","author":"Aykutlu","year":"2006","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0102","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1749-6632.2009.04670.x","article-title":"Cognitive functioning in Beh\u00e7et's disease","volume":"1173","author":"Cavaco","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0103","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1468-1331.1998.510049.x","article-title":"Subclinical cerebral involvement in Behcet's disease: a SPECT study","volume":"5","author":"Avci","year":"1998","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0104","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1017\/S0317167100052586","article-title":"P300 in Behcet's patients without neurological manifestations","volume":"28","author":"Kececi","year":"2001","journal-title":"Can J Neurol Sci J Can Sci Neurol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10067-011-1763-9","article-title":"The subclinic autonomic dysfunction in patients with Beh\u00e7et disease: an electrophysiological study","volume":"31","author":"Borman","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0106","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s004150050360","article-title":"Cyclosporine neurotoxicity: a review","volume":"246","author":"Gijtenbeek","year":"1999","journal-title":"J Neurol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0107","first-page":"170","article-title":"Neurotoxicity of immunosuppressive therapies in organ transplantation","volume":"8","author":"Anghel","year":"2013","journal-title":"Maedica (Buchar)"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0108","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0161-6420(99)90120-3","article-title":"Central nervous system symptoms in patients with Beh\u00e7et disease receiving cyclosporine therapy","volume":"106","author":"Kotake","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0109","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10067-005-0070-8","article-title":"CNS involvement occurs more frequently in patients with Beh\u00e7et's disease under cyclosporin A (CSA) than under other medications\u2013results of a retrospective analysis of 117 cases","volume":"25","author":"K\u00f6tter","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0110","first-page":"S84","article-title":"Cyclosporine for Beh\u00e7et's uveitis: is it associated with an increased risk of neurological involvement?","volume":"26","author":"Akman-Demir","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0111","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1007\/s00415-013-7150-5","article-title":"Efficacy of infliximab in neuro-Beh\u00e7et's disease presenting with isolated longitudinally extensive transverse myelitis","volume":"260","author":"Kuroda","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.semarthrit.2023.152206_bib0112","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2008.05.002","article-title":"Effect of infliximab in progressive neuro-Beh\u00e7et's syndrome","volume":"272","author":"Kikuchi","year":"2008","journal-title":"J Neurol Sci"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:10:27Z","timestamp":1758733827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223000483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":112,"alternative-id":["S0049017223000483"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152206","relation":{},"ISSN":["0049-0172"],"issn-type":[{"type":"print","value":"0049-0172"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic approach to central nervous system involvement of Beh\u00e7et's disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152206"}}